top of page
Search

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer


"Brief Summary

Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as to evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab."


At John Hopkins. Maryland

Phase 1, 30 patients

Opened May 2020


PLEASE NOTE: All interventional trials involve risk, so please discuss with your oncology team. And ask questions of the researchers e.g. patient responses and any side effects on treatment.


At the KRAS KICKERS 2024 Hope Filled Summit, Dr. Marrone of John Hopkins, had a presentation about KRAS vaccines in general as well as information on this trial at 13 minutes.












Genentech_Logo.png_dark blue text that reads, "Genetech." Gray italicized text that reads, "a member of the Roche Group."
Blue capitalized text on a gray background. Text reads, "Amgen."
Dark blue text on top of sea foam text. Text reads, "Verastem Oncology."
Black capitalized text that reads, "Revolution Medicine."
bottom of page